Author's response to reviews

Title: Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia

Authors:

Koichi Sakata (ksakata@wolf.or.jp)
Tatsuo Morita (moritatu@jichi.ac.jp)

Version: 2 Date: 27 January 2012

Author's response to reviews: see over
Dear Editors

The incidence of ejaculatory disorder by α1 blockers is mostly reported on the basis of adverse reaction reports in the clinical trials. The practical clinical application of silodosin started in Japan in 2006. The incidence of ejaculatory disorder in the phase III clinical study in Japan is reported as 22.3%. However, this incidence of ejaculatory disorder refers to the incidence in the patients treated with silodosin on the whole without taking the presence or absence of sexual actions into consideration. The true incidence of ejaculatory disorder should be calculated by investigating the patients who carried out sexual actions during the administration of α1 blocker. Accordingly, a questionnaire survey related to the ejaculatory disorder was conducted this time in the LUTS/BPH patients under treatment with silodosin to investigate the circumstance of ejaculatory disorder caused by silodosin among the patients who exercised sexual actions.

Sincerely yours